Details of the Drug Reposition

General Information of This Drug (ID: DMG281S)

• Drug Name: Carboplatin (DMG281S)
• Synonyms: Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)
• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

12 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Ovarian serous cystadenocarcinoma	DISMYAWR	N.A.	Approved	[1]
Ovarian neoplasm	DISEAFTY	N.A.	Approved	[1]
Ovarian disorder	DISHZX9D	N.A.	Approved	[1]
Lung adenocarcinoma	DISD51WR	N.A.	Approved	[1]
Fallopian tube neoplasm	DISHMMF2	N.A.	Approved	[1]
Carcinoma	DISH9F1N	2A00-2F9Z	Approved	[1]
Epithelial ovarian cancer	DIS56MH2	2B5D	Approved	[1]
Gastroesophageal junction adenocarcinoma	DISCVPML	2B71	Approved	[1]
Cholangiocarcinoma	DIS71F6X	2C12.10	Approved	[1]
Small-cell lung cancer	DISK3LZD	2C25.Y	Approved	[1]
Cutaneous melanoma	DIS3MMH9	2C30	Approved	[1]
Adenocarcinoma	DIS3IHTY	2D40	Approved	[1]

1 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Ovarian cancer	DISZJHAP	2C73	Withdrawn	[2]

2 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hepatobiliary neoplasm	DISSXKSB	N.A.	Discontinued in Phase 3	[3]
Esophageal adenocarcinoma	DISODWFP	N.A.	Discontinued in Phase 3	[4]

5 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Cancer of unknown primary site	DISSA12E	N.A.	Discontinued in Phase 2	[5]
Neoplasm of esophagus	DISOLKAQ	N.A.	Discontinued in Phase 2	[6]
Thyroid gland undifferentiated (anaplastic) carcinoma	DISYBB1W	N.A.	Discontinued in Phase 2	[7]
Anaplastic astrocytoma	DISSBE0K	2A00.0	Discontinued in Phase 2	[8]
Non-hodgkin lymphoma	DISS2Y8A	2B33.5	Discontinued in Phase 2	[9]

2 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Lung large cell carcinoma	DISUG64F	N.A.	Investigative	[1]
Neuroblastoma	DISVZBI4	2D11.2	Investigative	[1]

References

• [1] Carboplatin FDA Label
• [2] ClinicalTrials.gov (NCT00000372) Glycine and D-Cycloserine in Schizophrenia
• [3] Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
• [4] Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
• [5] A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer
• [6] Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
• [7] ClinicalTrials.gov (NCT01652014) Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
• [8] Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
• [9] Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer